Published 4 days ago • loading... • Updated 2 days ago

Character Biosciences raises $93M with an eye on vision loss drugs

Summary by biopharmadive.com

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed geographic atrophy medicines.

9 Articles

All

Left

Center

Right

biopharmadive.com

Center

Character Biosciences raises $93M with an eye on vision loss drugs

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed geographic atrophy medicines.

4 days ago

Read Full Article

portaldoriograndense.com

Revolutionizing Eye Care: The Race to Cure Age-Related Blindness Takes a Bold Step Forward

Character Biosciences has secured $93 million in Series B funding to transform the treatment of degenerative eye diseases, particularly age-related macular degeneration (AMD). AMD affects 1 in 8 individuals over 50 and is a leading cause of blindness among older adults globally. The company is developing breakthrough therapies, CTX203 and CTX114, targeting the mechanisms behind retinal cell death to halt or reverse vision loss. Collaboration wit…

2 days ago

Read Full Article

Inside Precision Medicine

Character Biosciences Achieves Oversubscribed Series B

Character Biosciences, a NJ-based ophthalmology-focused biotech, has raised $93 Million in Series B funding to develop precision medicine-based eye therapies for conditions such as age-related macular degeneration (AMD). The company is using a data-driven approach to reclassify common diseases such as AMD into genetic subtypes so treatment can be more targeted and effective for patients. The Series B round was co-led by Israel’s largest health t…

3 days ago

Read Full Article

Pharmaphorum

Character raises $93m for eye drugs, plus other financings

Recent financings in the biotech space include rounds for Character Bio, Tempero, Epicrispr, Hillstar Bio, and Ampersand Biomedicines.

3 days ago

Read Full Article

pharmaceutical-technology.com

Character Biosciences gains $93m for eye disease therapies

Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision therapies.

3 days ago

Read Full Article

MedCity News

Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD

Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech’s Series B round will finance clinical tests of two programs, each addressing a different stage of the disease. The post Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M f…

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year